Lupin receives USFDA’s approval for generic Dovonex Scalp Solution

28 Dec 2017 Evaluate

Lupin has received final approval for its Calcipotriene Topical Solution, 0.005% (Scalp Solution) from the United States Food and Drug Administration (USFDA) to market a generic version of Dovonex Scalp Solution, 0.005% of Leo Pharmaceutical Products.

Lupin's Calcipotriene Topical Solution, 0.005% (Scalp Solution) is the AT rated generic equivalent of Leo Pharmaceutical Products' Dovonex Scalp Solution, 0.005%. It is indicated for the topical treatment of chronic, moderately severe psoriasis of the scalp.

Calcipotriene Topical Solution, 0.005% (Scalp Solution) had annual sales of approximately $5.9 million in the US (IMS MAT October 2017).

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2043.30 6.25 (0.31%)
21-Nov-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1777.65
Dr. Reddys Lab 1194.55
Cipla 1465.65
Lupin 2043.30
Zydus Lifesciences 944.25
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.